Equities
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)5.52
  • Today's Change-0.17 / -2.99%
  • Shares traded6.32m
  • 1 Year change-22.91%
  • Beta0.8179
Data delayed at least 15 minutes, as of Nov 22 2024 08:08 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

3SBio Inc. is an investment holding company mainly engaged in the the development, production, marketing and sale of pharmaceutical products. The Company’s main products include recombinant human thrombopoietin (rhTPO) products, tumor necrosis factor (TNF)αinhibitor products and recombinant human erythropoietin (rhEPO) products. The products are sold under the name of TPIAO, Yisaipu, EPIAO and SEPO. The Company distributes its products within the domestic market and to overseas markets, including Sri Lanka, Dominican Republic and Thailand. The Company’s subsidiaries include Collected Mind Limited, Hongkong Sansheng Medical Limited and Shenyang Sunshine Pharmaceutical Co., Ltd.. Through its subsidiaries, the Company is engaged in project management and consultation.

  • Revenue in HKD (TTM)9.05bn
  • Net income in HKD1.78bn
  • Incorporated2006
  • Employees5.61k
  • Location
    3SBio IncNo. 3 A1, Road 10Shenyang Economy & TechnologyDevelopment ZoneSHENYANG 110027ChinaCHN
  • Phone+86 2 425811820
  • Fax+86 2 425811821
  • Websitehttps://www.3sbio.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Yichang Hec Changjiang Pharmactcl Co Ltd5.95bn1.77bn8.39bn4.89k4.740.90194.091.412.012.016.7610.580.42722.503.741,288,741.0011.698.0317.2711.8178.9079.9727.3720.801.9350.790.212615.8168.0820.182,501.2416.15-11.50--
AIM Vaccine Co Ltd1.27bn-1.28bn8.43bn1.56k--2.24--6.63-1.06-1.061.053.110.14620.63251.10783,272.40-22.69---37.16--72.34---155.22--0.6836-6.610.3437---6.06---307.07------
Luye Pharma Group Ltd6.78bn827.63m9.86bn5.23k11.910.70475.921.450.220.221.803.720.2362.443.021,286,903.003.112.805.474.4568.7370.5313.1810.391.203.140.410311.822.703.50-11.94-16.39-14.05--
Beijing Biostar Pharmaceuticals Co Ltd-100.00bn-100.00bn10.59bn--------------------------------------------------103.03---18.15------
Shanghai Henlius Biotech Inc6.06bn743.71m11.03bn3.55k14.873.989.671.821.371.3711.105.100.57641.906.821,665,945.007.07-8.5914.25-14.1473.2371.7712.27-27.370.3297.600.6113--67.82273.51178.53--49.14--
SSY Group Ltd6.47bn1.37bn11.27bn5.80k8.301.566.161.740.45930.45932.182.440.54182.753.071,155,141.0011.5410.5114.8814.0354.3958.7221.3018.622.0628.650.32338.560.45059.1017.447.663.9413.56
China Traditional Chinese Med Hldg CoLtd18.48bn985.51m11.38bn17.72k11.550.49585.060.61580.19570.19573.674.560.4531.541.821,068,071.002.624.604.017.0749.8657.075.779.771.517.390.180817.3526.699.9968.11-2.24-12.75--
Everest Medicines Ltd449.61m-1.13bn12.63bn520.00--2.62--28.09-3.51-3.511.3914.770.07565.233.221,040,759.00-19.03-30.52-20.21-33.1475.74---251.64-5,745.254.62--0.1119--884.46---241.50--4.65--
3SBio Inc9.05bn1.78bn13.63bn5.61k7.780.88226.171.510.73140.73143.716.450.35751.526.871,671,849.007.257.4410.269.2985.9482.9120.2721.501.57141.550.1998--13.8411.26-19.133.948.78--
Grand Pharmaceutical Group Ltd10.59bn2.41bn15.80bn10.78k6.461.005.491.490.68850.68853.034.430.44723.624.541,005,064.0010.2510.0914.2114.0159.0061.9722.9222.351.09--0.223226.9410.1212.06-9.5921.415.6924.77
Simcere Pharmaceutical Group Ltd6.81bn-1.19bn17.13bn6.41k--2.32--2.51-0.4528-0.45282.652.920.51982.192.64969,480.10-9.0410.17-11.7115.6077.0278.82-17.4017.501.880.47210.146146.684.497.92-23.22-0.521323.93--
The United Laboratories Intl. Hldgs Ltd.15.05bn3.12bn18.46bn15.00k5.911.274.941.231.721.728.288.000.65783.305.671,003,237.0013.657.8920.7212.6446.1544.1720.7512.731.72--0.153228.9921.2212.8470.8531.6624.1946.04
China Medical System Holdings Ltd7.53bn1.49bn18.66bn5.78k12.511.0810.782.480.61130.61133.087.080.3842.895.651,321,635.007.5118.448.5321.1474.1375.4719.5634.263.97--0.066740.14-12.438.08-26.335.3538.695.19
Data as of Nov 22 2024. Currency figures normalised to 3SBio Inc's reporting currency: Hong Kong Dollar HKD

Institutional shareholders

11.36%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 06 Nov 202465.62m2.72%
Dimensional Fund Advisors LPas of 07 Nov 202442.05m1.74%
HSBC Jintrust Fund Management Co. Ltd.as of 30 Jun 202433.28m1.38%
China Southern Asset Management Co., Ltd.as of 30 Jun 202428.22m1.17%
GF Fund Management Co., Ltd.as of 30 Jun 202426.57m1.10%
BlackRock Fund Advisorsas of 30 Oct 202421.15m0.88%
Bankinter Gesti�n de Activos SA SGIICas of 30 Jun 202418.95m0.78%
Norges Bank Investment Managementas of 30 Jun 202414.65m0.61%
Bosera Asset Management Co., Ltd.as of 30 Jun 202413.27m0.55%
Ninety One Hong Kong Ltd.as of 31 Jul 202410.68m0.44%
More ▼
Data from 30 Jun 2024 - 11 Nov 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.